Skip to content
MarketScale
‹ Back to Industries

Sciences

Material Signs: Introduction to the World of Optics

Doctors Scott Carney, chief science and technology officer at Optica, Kate Medicus, CEO at Ruda-Cardinal, and Alexis Vogt, endowed chair and professor of optics at Monroe Community College, joined Host Tyler Kern for the very first podcast of Enpro’s Material Signs to talk about the world of optics and its impact on the world. Optics,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Climate ChangeEnproMaterial SignsMonroe Community College
Share

Key takeaways

01

Doctors Scott Carney, chief science and technology officer at Optica, Kate Medicus, CEO at Ruda-Cardinal, and Alexis Vogt, endowed chair and professor of optics at Monroe Community College, joined Host Tyler Kern for the very first podcast of Enpro’s Material Signs to talk about the world of optics and its impact on the world.

Doctors Scott Carney, chief science and technology officer at Optica, Kate Medicus, CEO at Ruda-Cardinal, and Alexis Vogt, endowed chair and professor of optics at Monroe Community College, joined Host Tyler Kern for the very first podcast of Enpro’s Material Signs to talk about the world of optics and its impact on the world.

Optics, which is the science of light, is arguably the oldest science with its roots going back to 2,500 years ago with the law of reflection. Now, optics likely touches every aspect of modern life, expanding into many technologies, such as lasers, cell phones, computer chips, cameras, cars, and even champagne inspection machines.

It also is a big factor in helping solve bigger needs, like fighting global climate change, enabling space exploration, and assisting national security measures. Carney summed it up perfectly, saying: “I think it would be easier to identify the things that you interact with that don’t involve optics.”

Optics is prominent in nearly all industries and touches many different businesses. What excites Vogt the most about the endless opportunities is the ability to help impoverished areas. She explained, “Think about the technologies that are forthcoming … like having Wi-Fi access to all people around the entire world — even to developing countries that don’t have running water.”

Medicus expanded on how far the technology has come in just two short decades: “Over the last twenty years … we can manufacture the most oddly shaped glass elements, which allows us to have smaller optical systems, lighter-weight optical systems — or more precise optical systems — and that allows us to grow the technology and grow our innovation.”

Optics is changing the way people live, and each person, company, product, and technology plays a huge role in making that revolution happen.

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences